Clinical ChallengesPivotal development of TPIP is expected to be difficult, both in PAH and PH-ILD.
Product CompetitionLQDA shares are currently under pressure due to the recent positive results of a competing product, TPIP, in phase 2 trials.
Product EfficacyThe probability of success for YUTREPIA in PH-ILD has been lowered to 85% from 99% to reflect unresolved risk.